Close
0
You have no items in your order cart.
Search
Filters

Dog & Cat Vaccines

View as Grid List
Sort by
Display per page

Nobi-Vac Dhppi - 1ml x50

120240
A live vaccine against canine distemper, infectious canine hepatits, canine parvovirus and canine parainfluenza virus infection for use in dogs. For active immunisation of dogs against canine distemper, canine hepatitis, canine parvovirus with a three year minimum duration of immunity and canine parainfluenza virus with a one year duration of immunity. However, the company recommends that the first year annual booster should be a ‘full’ DHPPi and Lepto vaccination. Nobivac DHPPi contains live, attenuated, freeze dried canine distemper virus, canine adenovirus-2 (CAV2), canine parvovirus and canine parainfluenza virus. The vaccine contains attenuated antigens to stimulate active immunity in dogs against canine distemper virus, canine parvovirus, infectious canine hepatitis caused by canine adenovirus 1 and respiratory disease caused by canine adenovirus type 2 and canine parainfluenza virus.

Nobi-Vac Kc. - 1ml x5

121660
A live vaccine against canine infectious tracheobronchitis caused by B. bronchiseptica and parainfluenza virus in dogs. Infectious tracheobronchitis is a highly contagious, multi-factorial disease of the dog’s respiratory tract. Bordetella bronchiseptica and canine parainfluenza are the most common bacterial and viral agents associated with the disease. Environmental factors such as stress, ventilation and climate may also contribute. Nobivac KC is a low volume dose (0.4ml), easy to administer, intranasal vaccine which acts against both the key causative agents of infectious tracheobronchitis and provides protection within 72 hours and lasts for at least 12 months. It can be used in puppies as young as three weeks and in pregnant bitches.

Nobi-Vac L4 - 1ml x10

116904
Nobivac L4 is an inactivated vaccine containing a liquid suspension of Leptospira interrogans serogroup Canicola serovar Portland-vere (strain Ca-12-000), L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava and L. kirschneri serogroup Grippotyphosa serovar Dadas

Nobi-Vac L4 - 1ml x50

116894
Nobivac L4 is an inactivated vaccine containing a liquid suspension of Leptospira interrogans serogroup Canicola serovar Portland-vere (strain Ca-12-000), L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava and L. kirschneri serogroup Grippotyphosa serovar Dadas

Nobi-Vac Lepto 2 - 1ml x10

101901
Canine leptospirosis is caused by bacteria spread in the urine of infected animals. Leptospirosis is a serious infectious bacterial disease of dogs and a zoonotic risk to humans. Whilst a range of serovars may lead to disease in dogs, Nobivac Lepto 2 provides cover against the two serogroups most commonly implicated in clinical cases within the UK. Nobivac Lepto 2 is indicated for the active immunisation of dogs to reduce infection with Leptospira interrogans serogroup Canicola and Leptospira interrogans serogroup Icterohaemorrhagiae. The duration of immunity induced by the vaccine was established as at least one year. Nobivac Lepto 2 significantly reduces the number of animals which develop a urinary tract infection which can predispose to development of a carrier condition after L.interrogans serogroup Canicola and serogroup Icterohaemorrhagiae infection.

Nobi-Vac Parvo-C - 1ml x10

115240
Nobivac Parvo-C contains live, attenuated, freeze dried, virus vaccine containing canine parvovirus, grown in cell line tissue culture. Each vial contains a single dose for reconstitution prior to use. For active immunisation of dogs against canine parvovirus. Protects against CPV type 2, type 2a and type 2b. The company recommends that puppies are vaccinated with Nobivac DHPPi + Nobivac Lepto 2 twice, 2-4 weeks apart (or Nobivac L4 four weeks apart), with the final vaccination at an age of more than 10 weeks as a basic course of vaccination. If however prior to starting that basic vaccination course protection against CPV is required, an additional vaccination with Nobivac Parvo-C is advised.

Nobi-Vac Parvo-C - 1ml x50

121030
Nobivac Parvo-C contains live, attenuated, freeze dried, virus vaccine containing canine parvovirus, grown in cell line tissue culture. Each vial contains a single dose for reconstitution prior to use. For active immunisation of dogs against canine parvovirus. Protects against CPV type 2, type 2a and type 2b. The company recommends that puppies are vaccinated with Nobivac DHPPi + Nobivac Lepto 2 twice, 2-4 weeks apart (or Nobivac L4 four weeks apart), with the final vaccination at an age of more than 10 weeks as a basic course of vaccination. If however prior to starting that basic vaccination course protection against CPV is required, an additional vaccination with Nobivac Parvo-C is advised.

Nobi-Vac Rabies - 1ml

102181
Nobivac Rabies is an inactivated vaccine containing > 2 I.U. Rabies virus strain Pasteur RIV per dose. Also contains Aluminium phosphate as an adjuvant. 0.1 ml Thiomersal are added as a preservative. Owners wishing to take their pets abroad under the Pet Travel Scheme must ensure that they are microchipped and vaccinated against rabies. In order to provide sufficient time to meet the requirements of the Pet Passport travel scheme it is recommended that vaccination using MSD Animal Health vaccine against rabies should ideally be done at least three weeks before you travel to ensure animals are demonstrating evidence of immunity before embarking from the Republic of Ireland. They can then return to Ireland as long as a minimum of three weeks have elapsed since vaccination. For dogs or cats from the Republic of Ireland, it is stated on the Summary of Product Characteristics for Nobivac Rabies that “protective levels of circulating antibody are seen in all species within 30 days of vaccination”, data exist that an adequate serological response (≥0.5 IU) has been demonstrated 2 to 3 weeks after vaccination1. Immunity is reached within 30 days, and in keeping with legislation, travel after 21 days can be entered into the pet passport in the Republic of Ireland or Northern Ireland.

Nobivac Respira Bb - 10ml

158404
Nobivac® Respira Bb the first injectable vaccine for the protection of dogs against the clinical signs of upper respiratory tract disease caused by Bordetella bronchiseptica. The innovative new vaccine provides a familiar and convenient alternative to mucosal vaccination and is ideal for use in head-shy dogs and other circumstances where mucosal vaccination is not appropriate. The vaccine contains inactivated Bordetella bronchiseptica fimbriae in a ready-to-use liquid formulation and is available in a convenient ten-dose (10ml) vial which can be stored in or out of the fridge (up to 25°C) for 28 days after initial broaching. Nobivac® Respira Bb is licensed for use concurrently with other vaccines in the Nobivac range making it easy to fit into existing vaccination protocols. A single dose provides 12 months immunity after primary vaccination with Nobivac® KC.

Nobi-Vac Tricat Trio - 1ml x10

112331
Live vaccine containing per dose of 1 ml reconstituted vaccine:-Live attenuated feline calicivirus, strain F9-Live attenuated feline herpesvirus type 1, strain G2620A-Live attenuated feline panleucopenia virus, strain MW-1For the active immunisation of cats to reduce clinical signs caused by an infection with feline calicivirus (FCV) and feline herpes virus type 1 (FHV1) and to prevent clinical signs, virus excretion and leucopenia caused by feline panleucopenia virus (FPLV).

Purevax Felv - 1ml x10

104151
Feline leukaemia virus (FeLV) is contagious, lethal and incurable. FeLV can lead to the development of cancer in up to 30% of persistently infected cats and can suppress the immune system and bone marrow function, resulting in additional infectious diseases or anaemia. PUREVAX Recombinant FeLV vaccine: • Is the only non-adjuvanted feline leukaemia vaccine • Uses advanced recombinant canarypox-vectored vaccine technology • Comprehensive immune response PUREVAX Recombinant FelV contains a non-adjuvant lyophilized suspension of a recombinant vectored feline leukaemia vaccine plus sterile water diluent. A canarypox vector has been modified, using recombinant technology, to produce expression of desired antigens capable of stimulating a protective immune response to feline leukaemia. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible cats. Indications PUREVAX Recombinant FeLV is recommended for the vaccination of healthy cats 8 weeks of age or older as an aid in the prevention of disease due to feline leukaemia virus. Dosage Aseptically rehydrate the lyophilized vaccine with 1 ml of the accompanying sterile water diluent. and agitate. Administer 1 ml (1 dose) subcutaneously. For primary vaccination, cats should receive two 1-ml dose vaccinations, three weeks apart. Annual revaccination is recommended. Diagnostic testing for FelV prior to vaccination is recommend

Purevax Rcp Ch Felv - 1ml x10

104201
Active immunisation of cats aged 8 weeks and older against feline viral rhinotracheitis to reduce clinical signs; against calicivirus infection to reduce clinical signs and viral excretion; against Chlamydophila felis infection to reduce clinical signs; against feline panleucopenia to prevent mortality and reduce clinical signs; and against feline leukaemia to prevent persistent viraemia and reduce clinical signs of the disease. Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. The duration of immunity is 1 year after the last (re)vaccination for rhinotracheitis, calicivirus, Chlamydophila felis and feline leukaemia components, and 3 years for panleucopenia component. Dosage and administration 1 ml by subcutaneous injection after reconstitution of the freeze-dried pellet with the solvent according to the following schedule: Primary vaccination: First injection: from 8 weeks of age, Second injection: 3 to 4 weeks later. Revaccination: For all components one year after the primary vaccination course, then every year for the rhinotracheitis, calicivirosis, chlamydiosis and feline leukaemia components, and every three years for the panleucopenia component. Where high levels of maternal antibodies against R, C, P or Ch components are expected to be present (e.g. in kittens of 9 - 12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.